Retinoblastoma: Evaluation, Staging, Risk Stratification, and Management

Initial Evaluation and Workup

All children with suspected retinoblastoma require immediate fundoscopy under general anesthesia to visualize the entire retina, as this is the definitive diagnostic procedure 1, 2.

Key Diagnostic Steps:

Fundus examination under anesthesia is mandatory for complete visualization of all tumors, assessment of multifocality, and evaluation of vitreous seeding 1, 2
Ocular ultrasound to detect calcifications (present in >90% of cases) and assess tumor dimensions 1, 2
MRI of orbits and brain (preferred over CT to avoid ionizing radiation) to evaluate extraocular extension, optic nerve involvement, and rule out trilateral retinoblastoma (pineal gland involvement) 2, 3
Genetic testing for RB1 germline mutations in all patients, regardless of laterality, as 15% of unilateral cases are hereditary 4, 3

Critical Presenting Features to Document:

Leukocoria (most common, 60% of cases) and strabismus (20% of cases) are the primary presenting signs 2, 5
Bilaterality (indicates hereditary disease in 100% of cases) 4, 5
Age at presentation: bilateral cases present earlier (median 12-18 months) versus unilateral cases (median 24-36 months) 2, 3
Family history of retinoblastoma or retinoma 4

Staging Systems

The 8th Edition AJCC TNMH staging system is the current standard, incorporating tumor characteristics, nodal involvement, metastasis, and hereditary status 5.

Intraocular Classification (International Classification of Retinoblastoma):

Group A (very low risk): Small tumors ≤3mm away from fovea and optic disc 3, 5

Group B (low risk): All remaining discrete tumors confined to retina 3, 5

Group C (moderate risk): Discrete local subretinal and/or vitreous seeding ≤3mm from tumor 3, 5

Group D (high risk): Diffuse subretinal and/or vitreous seeding >3mm from tumor 3, 5

Group E (very high risk): Extensive retinoblastoma with neovascular glaucoma, massive intraocular hemorrhage, tumor anterior to anterior vitreous face, or phthisis bulbi 3, 5

Pathologic Risk Factors (Critical for Post-Enucleation Management):

Optic nerve invasion: prelaminar, laminar, retrolaminar, or to resection margin 4
Choroidal invasion (controversial but considered by many as metastatic risk factor) 4
Trans-scleral extension 4
Anterior chamber involvement 4

Risk Stratification

Hereditary vs. Non-Hereditary:

Bilateral or multifocal unilateral disease = 100% hereditary 4, 2
Unilateral unifocal disease = 85% non-hereditary, 15% hereditary 4, 3
All hereditary cases require lifelong surveillance for second malignant neoplasms, particularly sarcomas, melanoma, and uterine leiomyosarcoma 4

Metastatic Risk Factors:

Retrolaminar optic nerve invasion or involvement of resection margin 4, 6
Trans-scleral extension 4, 6
Massive choroidal invasion 4

Management by Stage

Group A-B (Early Intraocular Disease):

Focal therapy alone is the primary treatment for small, discrete tumors without seeding 6, 3.

Laser photocoagulation for small posterior tumors 6, 3
Cryotherapy for small anterior tumors 6, 3
Thermotherapy for small posterior tumors 6, 3
Examinations under anesthesia every 4-6 weeks for close monitoring and repeated focal treatments as needed 6

For Group B with suboptimal response, add 2-drug chemotherapy (vincristine + carboplatin) 6.

Group C-D (Advanced Intraocular Disease):

Systemic chemotherapy combined with intensive focal consolidation is the standard approach to preserve the eye and avoid radiation 6, 3.

Chemotherapy Regimens:

Group C: Vincristine + carboplatin (2-drug regimen) 6
Group D: Vincristine + carboplatin + etoposide (3-drug regimen is standard of care for advanced disease) 6
Alternative agents under investigation: Topotecan for improved intraocular penetration 6

Focal Consolidation (Applied During Each Examination Under Anesthesia):

Laser photocoagulation for posterior tumors 6, 3
Cryotherapy for anterior tumors 6, 3
Thermotherapy for medium-sized tumors 6, 3
Brachytherapy (radioactive plaques) for larger tumors not responding to other focal treatments 1, 6

Management of Vitreous Seeds:

Subconjunctival carboplatin for poor response of vitreous seeds to systemic chemotherapy 6
Intravitreal chemotherapy (melphalan or topotecan) for persistent vitreous seeding 3
Intracameral chemotherapy for anterior chamber seeding 3

Novel Delivery Methods:

Intraarterial chemotherapy (ophthalmic artery infusion of melphalan) for advanced intraocular disease 3
Periocular chemotherapy with slow-release devices under investigation 6

Group E (Very Advanced Intraocular Disease):

Enucleation is the primary treatment for Group E eyes, as salvage rates are extremely low and attempting preservation risks metastatic spread 6, 2, 3.

Post-Enucleation Pathology Assessment:

Histopathologic examination must document 4:

Optic nerve invasion by layer (prelaminar, laminar, retrolaminar, to resection margin)
Choroidal invasion depth
Trans-scleral extension
Anterior chamber involvement
Vitreous seeding presence

Adjuvant Chemotherapy Indications (After Enucleation):

Administer adjuvant chemotherapy if any high-risk pathologic features are present 6:

Retrolaminar optic nerve invasion
Tumor at optic nerve resection margin
Massive choroidal invasion
Trans-scleral extension

Regimen: Vincristine + carboplatin + etoposide for 6 cycles 6

Adjuvant Orbital Radiation Indications:

Add orbital external beam radiation (45 Gy) if 6:

Trans-scleral extension present
Tumor at cut end of optic nerve

Bilateral Disease Management:

The therapeutic goal is to cure the disease while preserving at least one eye with functional vision 6, 2.

Treatment Algorithm:

Enucleate the worse eye immediately if Group E 6, 2
Treat the better eye conservatively with chemotherapy + focal consolidation 6, 2
Use 2-drug regimen (vincristine + carboplatin) for Groups A-C 6
Use 3-drug regimen (add etoposide) for Group D 6
Examinations under anesthesia every 4-6 weeks with aggressive focal treatments 6

Radiation Therapy

External beam radiotherapy should be restricted to large ocular tumors and diffuse vitreous seeding that fail chemotherapy and focal treatments, due to high risk of secondary sarcomas in hereditary cases 2, 3.

Indications for External Beam Radiation:

Failure of chemotherapy + focal consolidation in Groups C-D 2
Diffuse vitreous seeding unresponsive to other treatments 2

Radiation Considerations:

Dose: 45-50 Gy in fractionated doses 2
Risk: Dramatically increases secondary malignancy risk, particularly sarcomas in radiation field, in hereditary cases 4
Minimize ionizing radiation exposure in all hereditary retinoblastoma patients, similar to Li-Fraumeni syndrome management 4

Enucleation: Specific Scenarios

Enucleation is indicated in the following clinical situations 6, 2, 3:

Absolute Indications:

Group E disease (neovascular glaucoma, massive hemorrhage, no light perception vision, phthisis) 6, 2, 3
Unilateral disease with no potential for useful vision 6, 2
Tumor progression despite maximal chemotherapy and focal treatments 6, 2
Diffuse infiltrating retinoblastoma unresponsive to treatment 2

Relative Indications:

Bilateral disease where one eye is Group E: enucleate worse eye, treat better eye conservatively 6, 2
Persistent active disease after 6-9 months of intensive treatment 6

Surgical Technique:

Obtain maximum optic nerve length (≥10mm preferred) 4
Send specimen fresh for potential genetic analysis if germline testing inconclusive 4

Extraocular and Metastatic Disease

Extraocular extension or metastatic disease requires intensive multimodal chemotherapy with poor prognosis (survival <50%) 5.

Treatment Approach:

High-dose chemotherapy with multiple agents 6, 5
Autologous hematopoietic stem cell rescue for consolidation 6
Orbital radiation for orbital disease 6
Systemic staging with bone marrow biopsy, lumbar puncture, bone scan 5

Surveillance and Long-Term Follow-Up

During Active Treatment:

Examinations under anesthesia every 4-6 weeks until tumor control achieved 6
MRI every 3-6 months for first 2 years to monitor for new tumors in hereditary cases 4

After Treatment Completion:

Examinations every 3-4 months for 2 years, then every 6 months until age 5 years 3
Annual ophthalmologic examinations lifelong for hereditary cases 4

Hereditary Retinoblastoma Survivors (Lifelong):

Annual dermatologic examination for melanoma surveillance 4
Annual history and physical with education about concerning symptoms (bone pain, masses) 4
Prompt evaluation of any new symptoms (whole-body MRI surveillance not routinely recommended due to lack of proven benefit) 4
Breast cancer screening per local guidelines starting age 40 4
Gynecologic awareness of uterine leiomyosarcoma risk (no effective screening available) 4

Critical Pitfalls to Avoid

Never delay genetic testing: 15% of unilateral cases are hereditary and require different surveillance 4, 3
Never use CT scans routinely: Minimize ionizing radiation in hereditary cases due to radiosensitivity 4
Never assume unilateral disease is non-hereditary: Always perform germline testing 4
Never undertake conservative treatment without examinations under anesthesia every 4-6 weeks: Tumor progression can be rapid 6
Never use external beam radiation as first-line: Reserve for failures of chemotherapy + focal therapy due to secondary malignancy risk 2, 3
Never ignore pathologic risk factors post-enucleation: Retrolaminar optic nerve invasion or positive margin mandates adjuvant chemotherapy 4, 6

What are the evaluation steps, staging, and management options for retinoblastoma, including chemotherapy, focal treatment, radiation, and enucleation?

Help us tailor your experience